Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$117.86 USD
-2.60 (-2.16%)
Updated Sep 20, 2024 03:14 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 33% (82 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.38 | 1.58 | 9.99 |
Current Quarter Estimate | 1.48 | -1.06 | 61.00 |
Year Ago Quarter Estimate | 0.82 | -0.06 | 54.84 |
Next Quarter Estimate | 1.61 | -1.85 | 63.00 |
Next Year Estimate | 7.07 | 12.67 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 69.64 | 20.70 | 15.67 |
Next Year | 68.74 | 16.20 | 11.34 |
Last 5 Years | 59.90 | 7.80 | 8.10 |
Next 5 Years | NA | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 36.39 | -1.82 |
Price/Book (MRQ) | 4.85 | 1.59 |
Price/Cash Flow (MRFY) | 46.71 | 9.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 16.00% | -61.35% |
Return on Equity (TTM) | 14.86% | -58.93% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.